GlassScriptPhysician profile
Daniel S Kirshenbaum
NPI 1164714697
$11,583.97
in general payments reported to CMS, 2019-2025
37 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $39.50 · 2021: $8,133 · 2022: $291 · 2023: $631 · 2024: $1,163 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,120.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiologs Technologies | $8,132.50 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $403.76 | 2022-2025 | Eliquis, Camzyos |
| Pfizer INC. | $398.74 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $261.68 | 2022-2025 | Verquvo, Gardasil 9, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $241.32 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $227.55 | 2023-2025 | Repatha, Otezla, Otezla |
| Janssen Biotech, INC. | $211.66 | 2022-2025 | Stelara, Tremfya, Simponi |
| Novo Nordisk INC | $168.59 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $141.33 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $129.17 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $126.72 | 2024 | Arcalyst |
| Heartflow, INC. | $92.00 | 2022-2023 | Ffrct |
| Lilly USA, LLC | $86.77 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $80.25 | 2022-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $75.17 | 2024-2025 | Onpattro, Amvuttra |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kirshenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.